Preferred Label : Ledipasvir/Sofosbuvir;
NCIt synonyms : Ledipasvir and Sofosbuvir; Ledipasvir-Sofosbuvir; Ledipasvir/Sofosbuvir Tablet; Ledipasvir Mixture with Sofosbuvir;
NCIt definition : A tablet containing a fixed dose combination of ledipasvir, an inhibitor of the hepatitis
C virus (HCV) non-structural protein 5A (NS5A) replication complex, and the prodrug
sofosbuvir, an inhibitor of HCV NS5B polymerase, with activity against HCV. Upon oral
administration of ledipasvir/sofosbuvir and intracellular uptake, ledipasvir binds
to and blocks the activity of the NS5A protein. This results in the disruption of
the viral RNA replication complex, blockage of HCV RNA production, and inhibition
of viral replication. Sofosbuvir is converted to its active triphosphate form, and
competes with uridine triphosphate for incorporation into RNA, thereby inhibiting
NS5B polymerase and preventing viral replication. This may eradicate HCV and prevent
HCV-mediated tumorigenesis. NS5A, a zinc-binding and proline-rich hydrophilic phosphoprotein,
plays a crucial role in HCV RNA replication. The HCV NS5B protein, an RNA-dependent
RNA polymerase, is essential for the replication of the viral HCV RNA genome. HCV
is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family;
HCV infection is associated with the development of certain tumors.;
Drug name : Harvoni;
Origin ID : C153378;
UMLS CUI : C3858051;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- concept_is_in_subset
